ClinicalTrials.gg

Mastocytosis, Systemic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 56 studies for Mastocytosis, Systemic across more than 10 countries. 16 are recruiting or about to start. 29 of them are mainly about Mastocytosis, Systemic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Leukemia, Mast-Cell too: 100 studies, 18 open.

Status

Completed
26
Recruiting
14
Active, not recruiting
4
Terminated
4
Status unknown
4
Withdrawn
1

Phase

Phase 2
22
Phase 1
9
Phase 3
5
Phase 4
2

Where

United States
33
France
18
Germany
16
Spain
13
Netherlands
13
Italy
13

Who develops what

Add Mastocytosis, Systemic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 23 Jun 2027 est.Avapritinib · Sanofi · Phase 2 main aimNCT03731260 (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis — primary endpoint: Part 1: Recommended Phase 2 dose (RP2D) in patients with ISM · 251 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Mastocytosis, Systemic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open

Coming up

5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Who these studies take

Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger. 4 (29%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.

Recruiting studies that take each age, of 14
AgeWomenMen
103 (21%)3 (21%)
1814 (100%)14 (100%)
3014 (100%)14 (100%)
4014 (100%)14 (100%)
5014 (100%)14 (100%)
6514 (100%)14 (100%)
7514 (100%)14 (100%)
8512 (86%)12 (86%)

Across all 56 studies, recruiting or not: 14% stop at 75 or younger and 2% at 65; 20% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 56. Browse all 56 → or search them.